BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BDTX-4933’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BDTX-4933 is under development for the treatment of multiple metastatic solid tumors including central nervous system (CNS) tumor, melanoma, non-small cell lung cancer, thyroid cancer and colorectal cancer. The drug candidates are developed based on MAP (mutation, allostery and pharmacology) platform. They are administered orally and acts by targeting a family of Class I (V600E), II, and III canonical and non-canonical serine/threonine protein kinase B-Raf (BRAF) alterations while avoiding paradoxical activation.
Black Diamond Therapeutics overview
Black Diamond Therapeutics (Black Diamond) is a precision oncology medicine company. It discovers small molecules and tumor agnostic therapies for the treatment of cancer. The company’s pipeline product candidates include BDTX- 4933 is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations; and BDTX-1535, a brain-penetrant small-molecule inhibitor for the treatment of glioblastoma, affecting the brain or spine. It is also developing its Mutation-Allostery-Pharmacology (MAP) technology platform, to identify oncogenic mutations that promote cancer. Black Diamond is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BDTX-4933’s drug-specific PTSR and LoA scores, buy the report here.